Stockreport

Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting

Beam Therapeutics Inc.  (BEAM) 
PDF All Seven Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of 60%, Hemoglobin S (HbS) Reduction to Initial Safety Profile Consistent with Busulfan [Read more]